⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1036629 | 0.86 | — | — | |
| SCHEMBL126850 | 0.86 | — | — | |
| SCHEMBL129692 | 0.85 | APLNR (0.31) | — | |
| SCHEMBL1039602 | 0.83 | — | — | |
| SCHEMBL23409727 | 0.78 | — | — | |
| SCHEMBL131618 | 0.74 | — | — | |
| SCHEMBL131068 | 0.72 | — | — | |
| SCHEMBL17913197 | 0.69 | — | — | |
| SCHEMBL21603134 | 0.65 | — | — | |
| SCHEMBL14128934 | 0.64 | ESR2 (0.41) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 136 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118161500-A | Heterocyclic compounds as delta-5 desaturase inhibitors and methods of use | 安进公司 | 2024-06-11 | — | — | CN | claimed |
| CN-114728167-B | Heterocyclic compounds as delta-5 desaturase inhibitors and methods of use | 安进公司 | 2024-03-19 | — | — | CN | claimed |
| EP-4260909-A2 | SUBSTITUTED INDAZOLES, PROCESS FOR THEIR PREPARATION, PHARMACEUTICAL PREPARATIONS CONTAINING THEM AND THEIR USE IN THE PREPARATION OF DRUGS | Bayer Pharma Aktiengesellschaft (DE) | 2023-10-18 | — | — | EP | claimed |
| US-20230159560-A1 | METHODS OF USING HETEROCYCLIC COMPOUNDS AS DELTA-5 DESATURASE INHIBITORS | APTUIT (VERONA) SRL, AN EVOTEC COMPANY (IT) | 2023-05-25 | — | — | US | claimed |
| US-20220249456-A1 | USE OF 2-SUBSTITUTED INDAZOLES FOR THE TREATMENT AND PROPHYLAXIS OF AUTOIMMUNE DISEASES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2022-08-11 | — | — | US | claimed |
| CN-114728167-A | Heterocyclic compounds as delta-5 desaturase inhibitors and methods of use | 安进公司 | 2022-07-08 | — | — | CN | claimed |
| US-20220204474-A1 | SUBSTITUTED INDAZOLES USEFUL FOR TREATMENT AND PREVENTION OF ALLERGIC AND/OR INFLAMMATORY DISEASES IN ANIMALS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2022-06-30 | — | — | US | claimed |
| EP-3464266-B1 | SUBSTITUTED INDAZOLES USEFUL FOR TREATMENT AND PREVENTION OF ALLERGIC AND/OR INFLAMMATORY DISEASES IN ANIMALS | BAYER ANIMAL HEALTH GMBH (DE) | 2021-10-20 | — | — | EP | claimed |
| US-20210221824-A1 | HETEROCYCLIC COMPOUNDS AS DELTA-5 DESATURASE INHIBITORS AND METHODS OF USE | AMGEN INC. | 2021-07-22 | — | — | US | claimed |
| US-20210188874-A1 | HETEROCYCLIC COMPOUNDS AS DELTA-5 DESATURASE INHIBITORS AND METHODS OF USE | AMGEN INC. | 2021-06-24 | — | — | US | claimed |
| CN-107406416-A | Novel substituted indazoles, method for the production thereof, pharmaceutical preparations containing same, and use thereof for producing medicaments | 拜耳医药股份有限公司 | 2017-11-28 | — | — | CN | claimed |
| US-9790198-B2 | Substituted benzothiophenyl derivatives as GPR40 agonists for the treatment of type II diabetes | JANSSEN PHARMACEUTICA NV (BE) | 2017-10-17 | — | — | US | claimed |
| US-20170290800-A1 | GPR40 AGONISTS IN ANTI-DIABETIC DRUG COMBINATIONS | JANSSEN PHARMACEUTICA NV (BE) | 2017-10-12 | — | — | US | claimed |
| EP-3224254-A1 | NEW SUBSTITUTED INDAZOLES, METHODS FOR THE PRODUCTION THEREOF, PHARMACEUTICAL PREPARATIONS THAT CONTAIN SAID NEW SUBSTITUTED INDAZOLES, AND USE OF SAID NEW SUBSTITUTED INDAZOLES TO PRODUCE DRUGS | Bayer Pharma Aktiengesellschaft (DE) | 2017-10-04 | — | — | EP | claimed |
| EP-3204361-A1 | SUBSTITUTED BENZOTHIOPHENYL DERIVATIVES AS GPR40 AGONISTS FOR THE TREATMENT OF TYPE II DIABETES | Janssen Pharmaceutica N.V. (BE) | 2017-08-16 | — | — | EP | claimed |
| CN-107001281-A | Substituted benzothiophene radical derivative is used as the GPR40 activators for treating type ii diabetes | 詹森药业有限公司 | 2017-08-01 | — | — | CN | claimed |
| WO-2016112088-A1 | ARYLOXYACETYLINDOLES AND ANALOGS AS ANTIBIOTIC TOLERANCE INHIBITORS | SPERO THERAPEUTICS, INC. (US) | 2016-07-14 | — | — | WO | claimed |
| WO-2016083433-A1 | NEW SUBSTITUTED INDAZOLES, METHODS FOR THE PRODUCTION THEREOF, PHARMACEUTICAL PREPARATIONS THAT CONTAIN SAID NEW SUBSTITUTED INDAZOLES, AND USE OF SAID NEW SUBSTITUTED INDAZOLES TO PRODUCE DRUGS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2016-06-02 | — | — | WO | claimed |
| WO-2016057731-A1 | SUBSTITUTED BENZOTHIOPHENYL DERIVATIVES AS GPR40 AGONISTS FOR THE TREATMENT OF TYPE II DIABETES | JANSSEN PHARMACEUTICA NV (BE) | 2016-04-14 | — | — | WO | claimed |
| US-20160102071-A1 | SUBSTITUTED BENZOTHIOPHENYL DERIVATIVES AS GPR40 AGONISTS FOR THE TREATMENT OF TYPE II DIABETES | JANSSEN PHARMACEUTICA NV (BE) | 2016-04-14 | — | — | US | claimed |